Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b Open-Label Study Assessing the Pharmacokinetics, Tolerability, and Safety of Oral Trimetazidine in Subjects With Acute-on-Chronic Liver Failure

NCT03737448 is registered in ClinicalTrials.gov with Martin Pharmaceuticals as lead sponsor.

NCT NCT03737448
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03737448 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b Open-Label Study Assessing the Pharmacokinetics, Tolerability, and Safety of Oral Trimetazidine in Subjects With Acute-on-Chronic Liver Failure
Lead sponsor
Martin Pharmaceuticals
Phase
Phase 1
Overall status
Suspended
Start date
November 28, 2018
Completion date
June 30, 2021
Enrollment
30 (estimated)
Sites
24

Conditions

As the registry lists them; a condition with its own page is linked.

acute-on-chronic liver failure